4-Aminopyridin-2-ol - Names and Identifiers
4-Aminopyridin-2-ol - Physico-chemical Properties
Molecular Formula | C5H6N2O
|
Molar Mass | 110.11 |
Density | 1.208±0.06 g/cm3(Predicted) |
Melting Point | 219-221 °C(Solv: acetone (67-64-1)) |
Boling Point | 310.7±35.0 °C(Predicted) |
Appearance | White to bright brown crystalline powder |
pKa | 11.49±0.10(Predicted) |
Storage Condition | under inert gas (nitrogen or Argon) at 2–8 °C |
4-Aminopyridin-2-ol - Risk and Safety
Hazard Symbols | Xn - Harmful
|
Risk Codes | 22 - Harmful if swallowed
|
4-Aminopyridin-2-ol - Introduction
It is an organic compound with the chemical formula C5H6N2O. It is a colorless crystalline solid, non-volatile at room temperature, soluble in water and some organic solvents.
It has a wide range of applications in the field of medicine. It can be used as a pharmaceutical intermediate for the synthesis of some drugs, such as trimethoprim (Methylbenzylamine) derivatives. In addition, it can also be used as an intermediate for pesticides. Other applications include use as catalysts and functional reagents in organic synthesis.
The preparation method of the calcium salt is generally achieved by chemical reaction. The common method is to produce 4-acetylamino-2-hydroxypyridine by the condensation reaction of acetanilide and pyridoxal, which is then obtained by aminolysis. The preparation method is relatively simple, but attention should be paid to controlling the reaction conditions to ensure the selectivity and yield of the reaction.
Regarding safety information, there is currently no detailed toxicity and hazard assessment, so safety measures should be taken when using. In general, inhalation of dust and contact with skin, eyes and mucous membranes should be avoided. It is recommended to wear personal protective equipment such as gloves and goggles during operation. If skin contact or accidental inhalation occurs, rinse immediately with water and seek medical help. When using this compound, local safety procedures and regulations should be strictly observed on a case-by-case basis.
Last Update:2024-04-09 20:52:54